Part of UT Health San Antonio

Part of UT Health San Antonio

You are here

John Erikson MD

Contact

210-450-4888

erikson@uthscsa.edu

Departments & Divisions

John M Erikson, MD

Professor

John Erikson, M.D., Ph.D., a cardiologist specializing in cardiovascular imaging, is Professor of Medicine in the Cardiology Division at The University of Texas Health Science Center in San Antonio, Texas and Program Director of the Cardiovascular Disease Fellowship. He is a staff physician at the University Health System’s University Hospital, Audie L. Murphy Memorial Veterans Administration Hospital, UT Health Physicians, and CHRISTUS Santa Rosa Medical Center, Medical Director of the University Hospital Non-Invasive Laboratories, and Medical Director of the Bartter Research Unit at the Audie L. Murphy Memorial Veteran’s Hospital.

After completing undergraduate study in biochemistry at North Texas State University, Dr. Erikson attended medical and graduate school at Southwestern Medical Center in Dallas, Texas where he received his M.D. and Ph.D. degrees, and completed his residency training at Parkland Memorial Hospital. He received his cardiology training at Southwestern Medical Center and received advanced echocardiography training at Washington University School of Medicine and Barnes Hospital before joining the faculty in San Antonio, where he participates in patient care, teaching, and clinical research. He has been elected to Fellowship in the American College of Cardiology, American Society of Echocardiography, and American Heart Association.

Dr. Erikson has received grant support from the Texas Affiliate of the American Heart Association to study proinflammatory cytokines in acute ischemia/reperfusion and investigating novel delivery techniques for gene therapy in the acute setting. His current research and clinical interests are related to non-invasive imaging, valvular heart disease, and percutaneous valve therapies. 

  • Professional Background

    Education

    • 1989 - MD - Medicine - UT Southwestern Medical School
    • 1988 - PhD - Biochemistry - UT Southwestern Graduate School of Biomedical Sciences
    • 1981 - BS - Biochemistry (Magna Cum Laude, University Honors) - North Texas State University
    • Internship - Internal Medicine - UT Southwestern Medical Center
    • Residency - Internal Medicine - UT Southwestern Medical Center
    • Postdoctoral Training - Cardiovascular Research - UT Southwestern Medical Center
    • Clinical Fellowship - Advanced Echocardiography - Washington University School of Medicine, Cardiology Division
    • Clinical Fellowship - Cardiovascular Disease - UT Southwestern Medical Center

    Appointments

    • 10/2017 - Holder/Manager, Roland K. Blumberg Endowment for Cardiovascular Research - UT Health Science Center at San Antonio, Medicine, San Antonio
    • 10/2014 - Centralized Echo Reviewer - Biomedical Systems/ERTSt. Louis
    • 10/2014 - Faculty Member - UT Health Science Center at San Antonio, Integrated Biomedical Sciences Program, San Antonio
    • 9/2010 - Professor of Medicine - UT Health Science Center at San Antonio, Medicine, San Antonio
    • 12/2005 - Staff Physician - Christus Santa Rosa Medical Center, Medicine, San Antonio
    • 7/1997 - Staff Physician - University Health System, Medicine, San Antonio
    • 7/1997 - Staff Physician - South Texas Veterans Health Care System, Audie L. Murphy Division, Medicine, San Antonio
    • 7/1997 - Staff Physician - UT Medicine at San Antonio, Medicine, San Antonio

  • Instruction & Training

    • 5/2020 - 5/2020, Cardiology Core Lecture - Congenital Heart Disease, UT Health Science Center at San Antonio
    • 1/1997 - Present, Rotation Student Supervision, UT Health Science Center at San Antonio
    • 1/1997 - Present, Rotation Student Supervision, UT Health Science Center at San Antonio
    • 1/1997 - Present, Rotation Student Supervision, UT Health Science Center at San Antonio

  • Research & Grants

    Grants

    Private

    Funding Agency Evalve, Inc. Title EVEREST II - A study of the Evalve Cardiovascular Valve Repair System (CVRS). Status Active Period 12/2004 - Present Role Co-Investigator Grant Detail   Funding Agency Edwards Lifesciences Corp Title The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII A (PARTNERII A) Status Active Period 9/2012 - 1/2029 Role Contributor Grant Detail The safety and effectiveness of the SAPIEN XT transcatheter heart valve with novaflex ASCENDRA/ASCENDRA II Delivery systems in intermediate risk for aortic valve surgery and patients who cannot undergo surgery Funding Agency Texas Alzheimer`s Research and Care Consortium Title Texas Alzheimer`s Research and Care Consortium Status Active Period 8/2018 - 8/2020 Role Contributor Grant Detail In summary, with this proposal we seek to utilize the cohort assembled by the TARCC in conjunction with participating clinics at UTHSCSA to help clarify the relationship between diastolic dysfunction and cognition. Repeated brain MRI will study structural change over time, and will include the novel analysis of the Alzheimer?s cortical signature7. Comprehensive neuropsychological testing will elucidate the pattern of cognitive impairment associated with diastolic dysfunction, which can help determine the extent of change in brain function. Results from this project will be of assistance in the development of new avenues of research for the prevention, treatment and management of dementia. The incidence rate of development of dementia would be significantly lowered by the correction of a widespread risk factor. At present, diastolic dysfunction is medically managed only when cardiac symptoms such as exercise intolerance or volume overload are present, as no therapy has been shown to improve the outcomes of all-cause or cardiovascular mortality and hospitalizations for heart failure11. If diastolic dysfunction is found to be associated with the development of cognitive impairment, increased emphasis on the treatment of diastolic dysfunction should be considered, such as with the use of rate-slowing agents, restoration of normal sinus rhythm, relieving volume overload, decreasing venous pressure, and controlling hypertension12. Funding Agency Eisai Pharmaceuticals Title Eisai APD356-A001-403. A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR? in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years. Status Active Period 10/2017 - 12/2019 Role Contributor Grant Detail   Funding Agency Eisai Pharmceuticals Title Eisai APD356-G000-401. CAMELLIA-TIMI 61 (Cardiovascular And Metabolic Effects of Lorcaserin In Overweight And Obese Patients) Status Complete Period 10/2014 - 10/2017 Role Contributor Grant Detail Eisai APD356-G000-401. CAMELLIA-TIMI 61 (Cardiovascular And Metabolic Effects of Lorcaserin In Overweight And Obese Patients) is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors.

  • Publications

      Journal Article

      Erikson JM, Valente AJ, Mummidi S, Kandikattu H, DeMarco VG, Bender SB, Fay WP, Siebenlist U, Chandrasekar B. Targeting TRAF3IP2 by genetic and interventional approaches inhibits ischemia/reperfusion-induced myocardial injury and adverse remodeling J Biol Chem 2017 Feb;262(6):2345-2358. Del Rincon I, Polak JF, O?Leary DH, Battafarano DF, Erikson JM, Restrepo JF, Molina E, Escalante A. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis Annals Rheum Dis 2015 Jan;74(6):1118-1123.

  • Clinical

    Board Certifications

    • American Board of Internal Medicine/Cardiovascular Disease